BRAF mutation in papillary thyroid carcinoma.

By Y. Cohen, Mingzhao Xing, E. Mambo, Zhongmin Guo, Guo-Qiang Wu, B. Trink, U. Beller, W. Westra, P. Ladenson, D. Sidransky. Journal of the National Cancer Institute, 2003

894 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/92dcca877b55b85ceaa139bc5a6d4a563d598971

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Gad Getz
2. Eric S. Lander
3. Matthew Meyerson
4. Kristian Cibulskis
5. Arul M. Chinnaiyan
6. M. Lawrence
7. Trey Ideker
8. Christopher Sander

In Molecular Biology

1. S. Baylin
2. Peter W. Laird
3. Trey Ideker
4. Eric S. Lander
5. Manel Esteller
6. Katherine A. Hoadley
7. J. Herman
8. Gad Getz

In Pulmonary and Respiratory Medicine

1. Arul M. Chinnaiyan
2. Marc Ladanyi

Citations in the corpus

• Integrated Genomic Characterization of Papillary Thyroid Carcinoma (2014, background): “…of genes encoding effectors in the mitogen-activated protein kinase (MAPK) signaling pathway, including point mutations of BRAF and the RAS genes (Cohen et al., 2003; Kimura et al., 2003; Lemoine et al., 1988; Suárez et al., 1988), as well as fusions involving the RET (Grieco et al., 1990) and…”
• Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study (2011, background): “For example, activating BRAF mutations have been described in more than 50% of cutaneous melanoma and papillary thyroid carcinoma, and the mutant proteins are potential targets for BRAF inhibitors (8, 9).”
• BRAF mutation in thyroid cancer. (2005, background): “The mutations in exon 11 of the BRAF gene found in other human cancers were not found in thyroid cancer (Cohen et al. 2003, Fukushima et al. 2003, Kimura et al. 2003, Namba et al. 2003, Frattini et al. 2004, Perren et al. 2004, Puxeddu et al. 2004).”
• Targeting the mitogen-activated protein kinase cascade to treat cancer (2004, neutral): “gov/cancertopics/pdq/treatment/thyroid/healthprofessional">thyroid origi”
• Molecular genetics and diagnosis of thyroid cancer (2011, background): “The most common mechanism of activation is a point mutation that involves a thymine to adenine substitution at nucleotide position 1799, which results in a valine-to-glutamate replacement at residue 600 (Val600Glu)”
• BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. (2003, background): “In another study, a higher prevalence (69%) of this mutation was observed in a series of 35 papillary carcinomas (10).”